Exercise and drug combo may fight fatigue in rare disease
NCT ID NCT07444333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether doing aerobic exercise at home, with or without the drug omaveloxolone, can safely improve fatigue and heart-lung fitness in people with Friedreich's ataxia. About 30 adults with the condition will take part. The goal is to see if the combination helps them feel less tired and move better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Genetically confirmed FRDA 2. Ability to safely ride a stationary bicycle (mFARS sitting posture sub-score \<2) Exclusion Criteria: 1. Beck depression score \>19, a score that precludes ability to exercise.30,31 2. Montreal Cognitive Assessment (MoCA) score \<23/30.32 3. Disorders that interfere with ability to perform endurance exercise (e.g., stroke, respiratory problems, traumatic brain injury, or neuromuscular disease). 4. Regular participation in vigorous endurance exercise (defined as \>2 days/week for at least the past 4 months at max HR\>65%). 5. Evidence of serious arrhythmias or ischemic heart disease.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Friedreich's ataxia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a missing protein be replaced to slow Friedreich's ataxia?
- Can advanced heart scans predict the biggest killer in Friedreich's ataxia?
- Experimental drug aims to halt rare neurological decline
- New brain scans could reveal hidden clues in rare nerve disease
- Genetic clues may predict when Friedreich's ataxia begins
- Can a supplement and exercise improve stamina in Friedreich's ataxia?